Cannabis Compounds May Reverse Fatty Liver Disease

Scientists at Hebrew University of Jerusalem just uncovered how cannabis compounds could help millions fighting a liver disease that affects one in three adults globally.

The breakthrough study found that CBD and CBG, two cannabis compounds that don't create a high, significantly reduced liver fat and improved metabolic health in experimental models. Both compounds work differently than THC, the psychoactive ingredient in cannabis, making them promising candidates for long-term medical treatment.

The research tackles Metabolic dysfunction-associated steatotic liver disease, a condition closely tied to obesity and insulin resistance. Right now, patients have very few approved drug treatments available.

Lead researcher Joseph Tam discovered something remarkable about how these compounds work. CBD and CBG help the liver produce more phosphocreatine, a molecule that stores energy in cells like a backup battery. This extra energy allows stressed livers to function more effectively, even when dealing with high-fat diets.

The compounds also restore enzymes called cathepsins, which act as cellular cleaning systems. These enzymes break down harmful fats and waste products inside cells, helping the liver remove dangerous lipids that trigger inflammation.

CBG showed particularly strong results in several areas. It reduced body fat, lowered LDL cholesterol, and improved insulin sensitivity in the experimental models.

Why This Inspires

This discovery represents more than just another cannabis study. It reveals a completely new biological pathway for treating a disease that's becoming increasingly common as obesity rates climb worldwide. The fact that these compounds don't cause intoxication means patients could potentially use them daily without affecting their ability to work, drive, or care for their families.

The research gives scientists fresh targets for developing treatments where few options currently exist. For the millions watching their liver health decline with limited solutions, this offers genuine hope for the future.

The team cautions that human clinical trials are still needed to confirm these results translate from lab models to actual patients. A separate JAMA review of over 2,500 cannabis studies highlighted important gaps between public perception and scientific evidence, reminding everyone that professional medical guidance remains essential.

Experts strongly recommend that anyone considering cannabinoid treatments consult healthcare professionals to understand both potential benefits and risks. The science shows promise, but the path from laboratory discovery to proven human treatment requires careful steps ahead.